Edwards Lifesciences Inc. (EW) - יחס חוב לטווח ארוך להון עצמי

Edwards Lifesciences (EW) generates revenue through the sale of advanced medical devices, with TAVR systems and patient monitoring equipment serving as the primary profit generators. The business maintains its leadership in the minimally invasive cardiac correction segment, replacing traditional surgery with innovations. The current metric stands at 0.06. This chart of the share price reflects a period of global implementation of new treatment methods and the expansion of sales markets.

This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, determining the degree of financial autonomy and the long-term stability of the balance sheet structure. By analyzing the long-term debt-to-equity ratio, an investor can see the conservative approach of Edwards Lifesciences (EW), where a steady cash flow from the sale of advanced transcatheter valves minimizes the need for debt financing.